Glycosaminoglycans
AssigneeAgency for Science, Technology and Research
InventorsSimon Cool, Victor Nurcombe
Life of this patent
Estimating the term…
Abstract
Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.
Claims15
A method of treating vascular disease, cardiovascular disease, heart disease, ischemia, ischemic disease, stroke, ischemic vascular disease, myocardial infarction, or a disease or condition characterised by decreased blood flow to tissues or organs due to blocked or partially blocked arteries in a patient, the method comprising administration of a therapeutically effective amount of isolated or substantially purified heparan sulphate HS7 to the patient, thereby stimulating or promoting growth of blood vessels in the patient;
- wherein
- HS7 is heparan sulphate having the disaccharide composition:
- Disaccharide
- Normalised weight percentage
- ΔUA,2S-GlcNS,6S
- 11.08 ± 3.0
- ΔUA,2S-GlcNS
- 4.46 ± 2.0
- ΔUA-GlcNS,6S
- 15.84 ± 3.0
- ΔUA,2S-GlcNAc,6S
- 4.76 ± 2.0
- ΔUA-GlcNS
- 20.27 ± 3.0
- ΔUA,2S-GlcNAc
- 1.01 ± 0.5
- ΔUA-GlcNAc,6S
- 10.63 ± 3.0
- ΔUA-GlcNAc
- 31.95 ± 3.0
- following digestion with heparin lyases I, II and III and then subjecting the resulting disaccharide fragments to capillary electrophoresis analysis;
- and
- HS7 is heparin-free and provides high activating affinity for VEGF.
A method of treating a vascular disease, cardiovascular disease, heart disease, ischemia, ischemic disease, stroke, ischemic vascular disease, myocardial infarction, or a disease or condition characterised by decreased blood flow to tissues or organs due to blocked or partially blocked arteries in a patient, the method comprising surgically implanting a biocompatible implant or prosthesis, which implant or prosthesis comprises a biomaterial and HS7, into tissue of the patient at or surrounding the wound or location at which blood vessel growth is required,
- wherein
- HS7 is heparan sulphate having the disaccharide composition:
- Disaccharide
- Normalised weight percentage
- ΔUA,2S-GlcNS,6S
- 11.08 ± 3.0
- ΔUA,2S-GlcNS
- 4.46 ± 2.0
- ΔUA-GlcNS,6S
- 15.84 ± 3.0
- ΔUA,2S-GlcNAc,6S
- 4.76 ± 2.0
- ΔUA-GlcNS
- 20.27 ± 3.0
- ΔUA,2S-GlcNAc
- 1.01 ± 0.5
- ΔUA-GlcNAc,6S
- 10.63 ± 3.0
- ΔUA-GlcNAc
- 31.95 ± 3.0
- following digestion with heparin lyases I, II and III and then subjecting the resulting disaccharide fragments to capillary electrophoresis analysis;
- and
- HS7 is heparin-free and provides high activating affinity for VEGF.
A method comprising administering isolated or substantially purified HS7 to vascular cells or vascular tissue in vivo, wherein growth of blood vessels is promoted.
Dependencies are inferred from the claim text.